scholarly journals Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Nada Madi ◽  
Widad Al-Nakib ◽  
Alexander Pacsa
Keyword(s):  
Kidney Transplant ◽  
Antiviral Treatment ◽  
Organ Transplant ◽  
Antiviral Resistance ◽  
Antiviral Prophylaxis ◽  
Wild Type ◽  
Transplant Patients ◽  
Kidney Transplant Patients ◽  
Treatment Sequencing ◽  
Ul54 Gene

The resistance of cytomegalovirus (CMV) to ganciclovir or valganciclovir is a factor in therapeutic failure and disease progression. CMV strains resistant to ganciclovir or valganciclovir have been associated with specific mutations in the UL97 and UL54 genes. Sequencing of both CMV UL97 and UL54 genes was performed to detect the presence of CMV antiviral resistance in six patients who received ganciclovir (and/or valganciclovir) and had prolonged detectable CMV DNA in their blood during antiviral treatment. Sequencing results showed no specific mutations in either UL97 or UL54 gene of CMV and therefore the CMV strains in kidney transplant patients who received ganciclovir either prophylactically or therapeutically were from the wild type. Our results suggest that CMV management and immunosuppression protocols for kidney transplant patients followed in the Organ Transplant Centre, Kuwait, is very effective in reducing the opportunity of developing CMV antiviral resistance.

scholarly journals Patterns of ocular morbidity among kidney transplant recipients in Ethiopia

2021 ◽  
Vol 7 (3) ◽  
pp. 155
Author(s):  
Lemlem Tamrat ◽  
Ewenat Gebrehanna
Keyword(s):  
Kidney Transplant ◽  
Dry Eye ◽  
Organ Transplant ◽  
Renal Diseases ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cross Sectional ◽  
Medical College ◽  
Transplant Patients ◽  
Kidney Transplant Patients

<p class="abstract"><strong>Background:</strong> Of all organ transplant procedures renal transplantation has become a very successful and routine procedure. Saint Paul’s Hospital Millennium Medical College is a pioneer and is the only center providing kidney transplant in Ethiopia. Even if this is a life changing and exiting addition to the countries’ health service coverage, its long term outcomes including various complications is not yet assessed. Therefore, the aim of this study is to describe ocular morbidities among kidney transplant recipients in Ethiopia.  </p><p class="abstract"><strong>Methods:</strong> Cross sectional descriptive study was undertaken from October 2017 to December 2018.  </p><p class="abstract"><strong>Results:</strong> There were a total of 135 individuals who underwent renal transplant procedure including 95 (70.4%) male and 40 (29.6 %) female. The median age was 32 years. The cause of renal diseases is not known in majority 112 (83%) of the study subjects. More than 95% of all the study subjects were on multiple immunosuppressant therapy. Of all the individuals examined 128 (94.8%) of them have one or more ocular morbidities. Dry eye 76 (50.7%), optic neuropathies 12 (8%), retinal pigmentary changes 11 (7.3%) and cataract 9 (6%) were frequently observed eye morbidities. There were no significant sight threatening conditions observed in relation to the immunosuppressive therapy or the diseases itself.</p><p class="abstract"><strong>Conclusions:</strong> Dry eye is the commonest eye morbidity among kidney transplant patients.</p>

Efficacy of Direct-Acting Antiviral Combination Therapy in the Treat-ment of Hepatitis C Virus Among Kidney Transplant Patients

2020 ◽  
Vol 18 ◽  
Author(s):  
Mohammed Al Atbee ◽  
Saad Shaheen Al-Taher ◽  
Majid Alabbood
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Kidney Transplant ◽  
Virological Response ◽  
Hepatitis C Virus Infection ◽  
Direct Acting Antiviral ◽  
Transplant Patients ◽  
Kidney Transplant Patients ◽  
Direct Acting

Background: Up to date, there is no consensus on the best combination of direct-acting antiviral to treat hepatitis C virus in kidney transplant recipients. Objective: This study aims to analyze the efficacy of combination of sofosbuvir and ledipasvir regimen for treatment of hepatitis C virus infected kidney transplant patients. Method: A cross-sectional study conducted in a nephrology clinic and the Nephrology Center in Basrah Teaching Hospital from June 2015 to June 2018. Ledifos (90 mg Ledipasvir and 400 mg Sofosbuvir fixed-dose) was given as a single daily dose for all the participants for 12 weeks. Response for therapy was tested by follow up hepatitis C virus load at the end of 12 weeks and 24 weeks. The sustained virological response was defined as negative viral load of hepatitis C virus (aviremia) at the end of therapy. This study was done according to the Helsinki Congress. Results: A total of 60 (16 females) patients with renal transplantation and hepatitis C virus infection were included. Mean age was 40±6.2 years. A sustained virological response observed in all of the patients who received Ledifos after 12 and 24 weeks of therapy for all genotypes (1a, 1b and 4); p= 0.0001. Genotype 1a was more prevalent among males, 34 (56.6%); p= 0.0001, and it was the most common genotype tested negative serologically, 11 (18.3%). Conclusion: Ledifos therapy is effective and safe option for the treatment of hepatitis C virus infection in the post–renal transplant setting.

Sign in / Sign up

Export Citation Format

Share Document